EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ocumension Therapeutics's enterprise value is HK$3,046.9 Mil.
Ocumension Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-382.0 Mil. Therefore, Ocumension Therapeutics's EV-to-EBITDA for today is -7.98.
The historical rank and industry rank for Ocumension Therapeutics's EV-to-EBITDA or its related term are showing as below:
HKSE:01477'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -28.2 Med: -8.51 Max: -0.86
Current: -7.98
During the past 6 years, the highest EV-to-EBITDA of Ocumension Therapeutics was -0.86. The lowest was -28.20. And the median was -8.51.
HKSE:01477's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs HKSE:01477: -7.98
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Ocumension Therapeutics's stock price is HK$5.96.
Ocumension Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-0.645. Therefore, Ocumension Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Ocumension Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Ocumension Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ocumension Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocumension Therapeutics EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ocumension Therapeutics's EV-to-EBITDA falls into.
Ocumension Therapeutics EV-to-EBITDA Calculation
Ocumension Therapeutics's EV-to-EBITDA for today is calculated as:
Ocumension Therapeutics's current Enterprise Value is HK$3,046.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ocumension Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-382.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Ocumension Therapeutics's PE Ratio for today is calculated as:
Ocumension Therapeutics's share price for today is HK$5.96.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ocumension Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-0.645.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Ocumension Therapeutics EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Ocumension Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Ocumension Therapeutics (HKSE:01477) Business Description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01477 has been successfully added to your 